| Literature DB >> 22971542 |
Loai Alzghoul1, Marco Bortolato, Foteini Delis, Panayotis K Thanos, Ryan D Darling, Sean C Godar, Junlin Zhang, Samuel Grant, Gene-Jack Wang, Kimberly L Simpson, Kevin Chen, Nora D Volkow, Rick C S Lin, Jean C Shih.
Abstract
Monoamine oxidase A (MAO-A) is the key enzyme for the degradation of brain serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE) and dopamine (DA). We recently generated and characterized a novel line of MAO-A hypormorphic mice (MAO-A(Neo)), featuring elevated monoamine levels, social deficits and perseverative behaviors as well as morphological changes in the basolateral amygdala and orbitofrontal cortex. Here we showed that MAO-A(Neo) mice displayed deficits in motor control, manifested as subtle disturbances in gait, motor coordination, and balance. Furthermore, magnetic resonance imaging of the cerebellum revealed morphological changes and a moderate reduction in the cerebellar size of MAO-A(Neo) mice compared to wild type (WT) mice. Histological and immunohistochemical analyses using calbindin-D-28k (CB) expression of Purkinje cells revealed abnormal cerebellar foliation with vermal hypoplasia and decreased in Purkinje cell count and their dendritic density in MAO-A(Neo) mice compared to WT. Our current findings suggest that congenitally low MAO-A activity leads to abnormal development of the cerebellum. Published by Elsevier Ltd.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22971542 PMCID: PMC3442946 DOI: 10.1016/j.neuropharm.2012.08.003
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250